HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A comparison of high-dose continuous and split-course irradiation in non-oat-cell carcinoma of the lung.

Abstract
From 1969 through 1979, 171 patients with localized but inoperable or unresectable non-oat-cell carcinoma (NOCC) of the lung completed high-dose definitive irradiation. One hundred fifteen received continuous course irradiation to 6000-6500 rad at 180-200 rad/day. Fifty-six received split-course irradiation to 5500 rad at 250-300 rad/day, which included a 2-week break. The two groups were similar with respect to all measured variables. There were no differences in the response rates, failure patterns, survival, or complication rates between the two regimens. The 5-year survival was 6%, with 25.8% dying with infield failure alone and 54.7% with metastases. The incidence of complications was 8.2%, predominantly acute radiation pneumonitis. A review of the most comparable literature reveals no significant improvement in the cure rate of definitively irradiated NOCC with increasing tumor dose, split-course irradiation, or other modifications of radiotherapeutic technique over the past 25 years. The problems of frequent local recurrences and distant metastases, and the poor response of NOCC to presently available systemic therapy, requires that more effective and broadly applicable local and systemic therapies be developed before substantial improvements in the cure rate of NOCC can be expected.
AuthorsH R Katz, R W Alberts
JournalAmerican journal of clinical oncology (Am J Clin Oncol) Vol. 6 Issue 4 Pg. 445-57 (Aug 1983) ISSN: 0277-3732 [Print] United States
PMID6307035 (Publication Type: Comparative Study, Journal Article)
Topics
  • Adult
  • Aged
  • Carcinoma, Small Cell (radiotherapy)
  • Female
  • Humans
  • Lung Neoplasms (radiotherapy)
  • Male
  • Middle Aged
  • Pneumonia (etiology)
  • Prognosis
  • Radiotherapy (adverse effects)
  • Radiotherapy Dosage

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: